Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a.
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SOUTH SAN FRANCISCO, Calif., June 23, 2023 (GLOBE NEWSWIRE) Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high
The Angelo State University Department of Communication and Mass Media hosted the COMMunication Research & Creativity Day showcase in the spine of the Houston Harte University Center on April 14